Literature DB >> 32231503

International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts.

Christoph Thomssen1, Diana Lüftner2, Michael Untch3, Renate Haidinger4, Rachel Würstlein5, Nadia Harbeck5, Doris Augustin6, Susanne Briest7, Johannes Ettl8, Peter A Fasching9, Frank Förster10, Christian M Kurbacher11, Hans-Joachim Lück12, Norbert Marschner13, Lothar Müller14, Volkmar Müller15, Lidia Perlova-Griff16, Isabel Radke17, Eugen Ruckhäberle18, Iris Scheffen19, Eva Schumacher-Wulf20, Moritz Schwoerer21, Dieter Steinfeld-Birg22, Katja Ziegler-Löhr23.   

Abstract

The 5th International Consensus Conference for Advanced Breast Cancer (ABC5) took place on November 14-16, 2019, in Lisbon, Portugal. Its aim is to standardize the treatment of advanced breast cancer based on the available evidence and to ensure that all breast cancer patients worldwide receive adequate treatment and access to new therapies. This year, the conference focused on developments and study results in the treatment of patients with hormone receptor-positive/HER2-negative breast cancer as well as precision medicine. As in previous years, patient advocates from around the world were integrated into the ABC conference and had seats on the ABC consensus panel. In the present paper, a working group of German breast cancer experts comments on the results of the on-site ABC5 consensus votes by ABC panelists regarding their applicability for routine treatment in Germany. These comments take the recommendations of the Breast Committee of the Gynecological Oncology Working Group (Arbeitsgemeinschaft Gynäkologische Onkologie; AGO) into account. The report and assessment presented here pertain to the preliminary results of the ABC5 consensus. The final version of the statements will be published in Annals of Oncology and The Breast.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  5th International Consensus Conference for Advanced Breast Cancer; Advanced breast cancer; BRCA-associated advanced breast cancer; Hormone receptor-positive and HER2-positive advanced breast cancer; Personalized medicine; Triple-negative advanced breast cancer

Year:  2020        PMID： 32231503      PMCID： PMC7098316          DOI： 10.1159/000505957

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


  35 in total

1.  3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).

Authors:  F Cardoso; A Costa; E Senkus; M Aapro; F André; C H Barrios; J Bergh; G Bhattacharyya; L Biganzoli; M J Cardoso; L Carey; D Corneliussen-James; G Curigliano; V Dieras; N El Saghir; A Eniu; L Fallowfield; D Fenech; P Francis; K Gelmon; A Gennari; N Harbeck; C Hudis; B Kaufman; I Krop; M Mayer; H Meijer; S Mertz; S Ohno; O Pagani; E Papadopoulos; F Peccatori; F Penault-Llorca; M J Piccart; J Y Pierga; H Rugo; L Shockney; G Sledge; S Swain; C Thomssen; A Tutt; D Vorobiof; B Xu; L Norton; E Winer
Journal:  Breast       Date:  2016-12-05       Impact factor: 4.380

2.  1st International consensus guidelines for advanced breast cancer (ABC 1).

Authors:  F Cardoso; A Costa; L Norton; D Cameron; T Cufer; L Fallowfield; P Francis; J Gligorov; S Kyriakides; N Lin; O Pagani; E Senkus; C Thomssen; M Aapro; J Bergh; A Di Leo; N El Saghir; P A Ganz; K Gelmon; A Goldhirsch; N Harbeck; N Houssami; C Hudis; B Kaufman; M Leadbeater; M Mayer; A Rodger; H Rugo; V Sacchini; G Sledge; L van't Veer; G Viale; I Krop; E Winer
Journal:  Breast       Date:  2012-03-16       Impact factor: 4.380

3.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).

Authors:  F Cardoso; A Costa; L Norton; E Senkus; M Aapro; F André; C H Barrios; J Bergh; L Biganzoli; K L Blackwell; M J Cardoso; T Cufer; N El Saghir; L Fallowfield; D Fenech; P Francis; K Gelmon; S H Giordano; J Gligorov; A Goldhirsch; N Harbeck; N Houssami; C Hudis; B Kaufman; I Krop; S Kyriakides; U N Lin; M Mayer; S D Merjaver; E B Nordström; O Pagani; A Partridge; F Penault-Llorca; M J Piccart; H Rugo; G Sledge; C Thomssen; L Van't Veer; D Vorobiof; C Vrieling; N West; B Xu; E Winer
Journal:  Breast       Date:  2014-09-20       Impact factor: 4.380

Review 4.  AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019.

Authors:  Nina Ditsch; Michael Untch; Marc Thill; Volkmar Müller; Wolfgang Janni; Ute-Susann Albert; Ingo Bauerfeind; Jens Blohmer; Wilfried Budach; Peter Dall; Ingo Diel; Peter A Fasching; Tanja Fehm; Michael Friedrich; Bernd Gerber; Volker Hanf; Nadia Harbeck; Jens Huober; Christian Jackisch; Cornelia Kolberg-Liedtke; Hans-Heinrich Kreipe; David Krug; Thorsten Kühn; Sherko Kümmel; Sibylle Loibl; Diana Lüftner; Michael Patrick Lux; Nicolai Maass; Volker Möbus; Markus Müller-Schimpfle; Christoph Mundhenke; Ulrike Nitz; Kerstin Rhiem; Achim Rody; Marcus Schmidt; Andreas Schneeweiss; Florian Schütz; Hans-Peter Sinn; Christine Solbach; Erich-Franz Solomayer; Elmar Stickeler; Christoph Thomssen; Frederik Wenz; Isabell Witzel; Achim Wöckel
Journal:  Breast Care (Basel)       Date:  2019-08-06       Impact factor: 2.860

5.  Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.

Authors:  Seock-Ah Im; Yen-Shen Lu; Aditya Bardia; Nadia Harbeck; Marco Colleoni; Fabio Franke; Louis Chow; Joohyuk Sohn; Keun-Seok Lee; Saul Campos-Gomez; Rafael Villanueva-Vazquez; Kyung-Hae Jung; Arunava Chakravartty; Gareth Hughes; Ioannis Gounaris; Karen Rodriguez-Lorenc; Tetiana Taran; Sara Hurvitz; Debu Tripathy
Journal:  N Engl J Med       Date:  2019-06-04       Impact factor: 91.245

6.  Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.

Authors:  Martin R Stockler; Vernon J Harvey; Prudence A Francis; Michael J Byrne; Stephen P Ackland; Bernie Fitzharris; Guy Van Hazel; Nicholas R C Wilcken; Peter S Grimison; Anna K Nowak; M Corona Gainford; Akiko Fong; Lisa Paksec; Tatiana Sourjina; Diana Zannino; Val Gebski; R John Simes; John F Forbes; Alan S Coates
Journal:  J Clin Oncol       Date:  2011-10-24       Impact factor: 44.544

7.  The NAME trial: a direct comparison of classical oral Navelbine versus Metronomic Navelbine in metastatic breast cancer.

Authors:  Sven Tyge Langkjer; Julia Kenholm; Jeanette Dupont Jensen; Kim Wedervang; Annette Torbøl Brixen; Mie Grunnet; Lars Stenbygaard; Bjørnar Gilje; Hella Danø; Vesna Glavicic; Erik Hugger Jacobsen; Anne Sofie Brems-Eskildsen; Helle Lemvig Kruse; Trine Dongsgaard; Jeppe Neimann; Jürgen Geisler
Journal:  Future Oncol       Date:  2019-06-19       Impact factor: 3.404

8.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Authors:  Kathy Miller; Molin Wang; Julie Gralow; Maura Dickler; Melody Cobleigh; Edith A Perez; Tamara Shenkier; David Cella; Nancy E Davidson
Journal:  N Engl J Med       Date:  2007-12-27       Impact factor: 91.245

9.  Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry.

Authors:  Andreas D Hartkopf; Jens Huober; Bernhard Volz; Naiba Nabieva; Florin-Andrei Taran; Judith Schwitulla; Friedrich Overkamp; Hans-Christian Kolberg; Peyman Hadji; Hans Tesch; Lothar Häberle; Johannes Ettl; Michael P Lux; Diana Lüftner; Markus Wallwiener; Volkmar Müller; Matthias W Beckmann; Erik Belleville; Pauline Wimberger; Carsten Hielscher; Matthias Geberth; Nikos Fersis; Wolfgang Abenhardt; Christian Kurbacher; Rachel Wuerstlein; Christoph Thomssen; Michael Untch; Peter A Fasching; Wolfgang Janni; Tanja N Fehm; Diethelm Wallwiener; Sara Y Brucker; Andreas Schneeweiss
Journal:  Breast       Date:  2017-10-26       Impact factor: 4.380

10.  Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.

Authors:  Stephen Rd Johnston; Lucy S Kilburn; Paul Ellis; David Dodwell; David Cameron; Larry Hayward; Young-Hyuck Im; Jeremy P Braybrooke; A Murray Brunt; Kwok-Leung Cheung; Rema Jyothirmayi; Anne Robinson; Andrew M Wardley; Duncan Wheatley; Anthony Howell; Gill Coombes; Nicole Sergenson; Hui-Jung Sin; Elizabeth Folkerd; Mitch Dowsett; Judith M Bliss
Journal:  Lancet Oncol       Date:  2013-07-29       Impact factor: 41.316
View more
  7 in total

Review 1.  Treatments on the Horizon: Breast Cancer Patients with Central Nervous System Metastases.

Authors:  Aaron Kaplan; Min Jun Li; Rachna Malani
Journal:  Curr Oncol Rep       Date:  2022-02-09       Impact factor: 5.075

2.  Awareness and Availability of Routine Germline BRCA1/2 Mutation Testing in Patients with Advanced Breast Cancer in Germany.

Authors:  Michael P Lux; Thomas Decker; Eva Diana Runkel; Alexander Niyazov; Ruben G W Quek; Norbert Marschner; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2021-02-18       Impact factor: 2.860

3.  Quality of Life Effects of an Oral Fixed Combination of Netupitant and Palonosetron in Chemotherapy-Induced Nausea and Vomiting Prevention: Real-World Evidence in Patients with Breast Cancer Receiving Anthracycline-Cyclophosphamide-Based Chemotherapy.

Authors:  Jörg Schilling; Christian M Kurbacher; Claus Hanusch; Steffi Busch; Martin Holländer; Janine Kreiss-Sender; Daniela Rezek; Elisa Flahaut; Meinolf Karthaus
Journal:  Breast Care (Basel)       Date:  2021-05-25       Impact factor: 2.268

4.  First Experiences with Alpelisib in Clinical Routine: Case Reports from a German Breast Center.

Authors:  Anna Hester; Franziska Henze; Christiane Travi; Nadia Harbeck; Rachel Wuerstlein
Journal:  Breast Care (Basel)       Date:  2021-03-15       Impact factor: 2.860

5.  Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer-results of an exploratory case-control study.

Authors:  S Krajnak; C Schnatz; K Almstedt; W Brenner; F Haertner; A-S Heimes; A Lebrecht; G-M Makris; R Schwab; A Hasenburg; M Schmidt; M J Battista
Journal:  Breast Cancer Res Treat       Date:  2020-06-03       Impact factor: 4.872

Review 6.  Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer.

Authors:  Élia Cipriano; Alexandra Mesquita
Journal:  Breast Cancer (Auckl)       Date:  2021-03-22

7.  Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program.

Authors:  Marion Bertho; Julien Fraisse; Anne Patsouris; Paul Cottu; Monica Arnedos; David Pérol; Anne Jaffré; Anthony Goncalves; Marie-Paule Lebitasy; Véronique D'Hondt; Florence Dalenc; Jean-Marc Ferrero; Christelle Levy; Sandrine Dabakuyo; Roman Rouzier; Frédérique Penault-Llorca; Lionel Uwer; Jean-Christophe Eymard; Mathias Breton; Michaël Chevrot; Sébastien Thureau; Thierry Petit; Gaëtane Simon; Jean-Sébastien Frénel
Journal:  Ther Adv Med Oncol       Date:  2021-01-21       Impact factor: 8.168
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.